What can be administered to prevent congenital rubella?

In the context of preventing congenital rubella syndrome, the administration of IVIG (intravenous immunoglobulin) is an important consideration when a pregnant woman has been exposed to rubella. If a pregnant woman, especially during the first trimester, is exposed to the rubella virus and is not immune, administering IVIG can help mitigate the risk of transmission to the fetus and, consequently, reduce the incidence of congenital rubella syndrome.

While the MMR vaccine is effective for prevention of rubella infection, it is contraindicated during pregnancy because it contains live attenuated virus. Therefore, while it is critical for women to be vaccinated against rubella before pregnancy to ensure immunity, it cannot be given during pregnancy as a preventive measure.

The other options, such as antibiotics and steroids, do not have a role in preventing rubella or its complications. Antibiotics target bacterial infections and are ineffective against viral infections like rubella. Steroids might be used in different clinical settings but do not prevent viral infections or congenital rubella syndrome.

Thus, the correct preventive measure following exposure in a non-immune pregnant woman is the administration of IVIG, as it can confer passive immunity and help protect the developing fetus from the consequences of rubella infection.